FIG. 2.
Schematic of the PS-DNase assay for episomal rAAV genomes. The predicted outcomes of treating rAAV-transduced muscle DNA with selected restriction enzymes in combination with PS-DNase are shown in this diagram. In the case of treatment with an enzyme that cuts once within the genome (Single Cutter), subsequent treatment with PS-DNase leads to degradation of all rAAV genomes, regardless of their forms (episomal or integrated). In the second case, when the total DNA is cut with an enzyme that does not cut within the rAAV genome (Zero Cutter), after treatment with PS-DNase, integrated forms are degraded while episomal forms are protected.